共 222 条
[1]
Singh JA(2012)2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res 64 625-639
[2]
Furst DE(2014)EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update Ann Rheum Dis 73 492-509
[3]
Bharat A(2009)Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis J Rheumatol 36 1429-1210
[4]
Curtis JR(2011)The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy Arthritis Rheum 63 1200-38
[5]
Kavanaugh AF(2013)Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study Arthritis Rheum 65 28-16
[6]
Kremer JM(2019)Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial Scand J Rheumatol 48 9-1431
[7]
Smolen JS(2018)Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes Rheumatology. 57 1423-638
[8]
Landewe R(2020)Pooled analysis of TNF inhibitor biosimilar studies comparing radiographic progression by disease activity states in rheumatoid arthritis RMD Open 6 e001096-1144
[9]
Breedveld FC(2012)Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations Arthritis Rheum 64 630-2967
[10]
Buch M(2017)Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need Rheumatology. 57 1135-263